Dark

VIVO
Meridian Bioscience Inc
stock NASDAQ

Inactive

Jan 30, 2023

33.97USD0.000%(0.00)6,422,835

Pre-market

0.00USD-100.000%(-33.97)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 31, 2022

11:51AM EST Meridian Bioscience Receives Additional NIH Award To Support Rapid Development Of Revogene Molecular Viral Respiratory Testing Panel; Total Amount ~$2.5M Benzinga

11:45AM EST Development of the Revogene(r) Molecular Viral Respiratory Testing Panel PR Newswire

Jan 28, 2022

10:07AM EST Meridian Bioscience Launches Lyo-Ready qPCR Saliva-Specific Master Mixes For DNA & RNA Direct Detection Benzinga

10:05AM EST Meridian Bioscience Launches Lyo-Ready(tm) qPCR Saliva-Specific Master Mixes PR Newswire

Jan 27, 2022

02:05PM EST Meridian Bioscience Elects John C. McIlwraith New Chairman of the Board PR Newswire

Jan 10, 2022

10:05AM EST Meridian Bioscience to Hold First Quarter 2022 Financial Results Conference PR Newswire

Jan 5, 2022

10:18AM EST Meridian Bioscience Received FDA-Clearance for the Benzinga

10:15AM EST Meridian Bioscience Receives FDA-Clearance for the Curian(r) Campy Assay PR Newswire

Jan 4, 2022

02:00PM EST Meridian Bioscience to Participate in the 2022 H. C. Wainwright Bioconnect PR Newswire

Dec 27, 2021

12:21PM EST FDA Issues 510(k) Premarket Notification For Meridian Bioscience curian campy Device Benzinga

Dec 22, 2021

02:35PM EST FDA Website Shows Dec. 22-Dated update On Antigen Tests For Omicron: 'The FDA continues to monitor and evaluate the impact of genetic variants on antigen tests...' Benzinga

Dec 9, 2021

09:54PM EST Meridian Bioscience Says Added New Info About Revogene COVID-19 Test; Says Test Is Expected To Fail To Detect Omicron Variant; FDA Says Co Will Not Distribute Test Until Issue Is Resolved Benzinga

Dec 2, 2021

08:14AM EST Meridian Bioscience Announces Retirement Of CFO Bryan Baldasare Benzinga

08:06AM EST Meridian Bioscience CFO Bryan Baldasare To Retire, Effective Dec .31 RTTNews

08:00AM EST Meridian Bioscience Announces Retirement of CFO Bryan Baldasare PR Newswire

Nov 24, 2021

09:07AM EST Meridian Bioscience Chairman David Phillips To Retire RTTNews

09:05AM EST Meridian Bioscience Announces Retirement of Chairman David Phillips PR Newswire

Nov 17, 2021

10:05AM EST Meridian Launches Two New Air-Dryable(tm) Mixes for Isothermal Amplification, PR Newswire

Nov 15, 2021

10:50AM EST HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $28 Benzinga

Nov 12, 2021

11:45AM EST Meridian Bioscience's Q4 Earnings Beat Expectations Benzinga

07:47AM EST The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares Benzinga

07:45AM EST Meridian Bio Sees FY22 Net Sales $285M-$300M vs $310.1M Estimate, Adj. EPS $0.98-$1.08 vs $1.63 Est. Benzinga

07:43AM EST Meridian Bioscience Q4 Adj. EPS $0.23 Beats $0.20 Estimate, Sales $76.20M Beat $68.40M Estimate Benzinga

07:32AM EST Meridian Bioscience Q4 Consolidated Net Revenues $76.2 Mln, Up 19% Year-over-year RTTNews

07:30AM EST Meridian Bioscience Reports Strong Fourth Quarter And Record Full-Year Fiscal PR Newswire

04:26AM EST Earnings Scheduled For November 12, 2021 Benzinga

Nov 11, 2021

10:59AM EST A Preview Of Meridian Bioscience's Earnings Benzinga

Nov 10, 2021

09:19AM EST Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Nov. 10, 2021: COIN, PLTR, DASH, VIVO, QIPT Benzinga

09:08AM EST Meridian Bioscience Inc.'s (VIVO) Revogene SARS-CoV-2 assay was granted Emergency Use Authorization by the U.S. Food and Drug Administration, the company said in a statement. RTTNews

08:57AM EST Meridian Bioscience Gets FDA Emergency Use Authorization For Revogene SARS-CoV-2 Molecular Assay RTTNews

08:56AM EST Meridian Bioscience Receives FDA Emergency Use Authorization For Revogene SARS-CoV-2 Molecular Assay Benzinga

08:55AM EST Meridian Bioscience Receives FDA Emergency Use Authorization for Revogene(r) PR Newswire

Oct 27, 2021

10:05AM EDT Meridian Launches Air-Dryable qPCR Mixes Enabling Direct Detection Of DNA Or RNA from Urine Samples Benzinga

10:05AM EDT Meridian Launches Innovative Air-Dryable(tm) qPCR Mixes Enabling Direct PR Newswire

Oct 14, 2021

02:05PM EDT Meridian Bioscience to Hold Fourth Quarter and Full Year 2021 Financial Results PR Newswire

Oct 7, 2021

02:01PM EDT Meridian Launches New Air-Dryable qPCR Mix Enabling Direct Detection Of RNA From Whole Blood Samples Benzinga

02:00PM EDT Meridian Launches New Air-Dryable(tm) qPCR Mix Enabling Direct Detection of RNA PR Newswire

Sep 9, 2021

01:15PM EDT Meridian Bioscience's Return on Invested Capital Insights Benzinga

10:01AM EDT Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA Or RNA From Stool Samples Benzinga

10:00AM EDT Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct GlobeNewswire Inc

Sep 7, 2021

10:02AM EDT Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection Of DNA Or RNA From Saliva Samples Benzinga

10:00AM EDT Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct GlobeNewswire Inc

Sep 2, 2021

07:58AM EDT Meridian Bioscience Expands Voluntary Recall of LeadCare Test Kits Benzinga

Sep 1, 2021

04:31PM EDT Meridian Bioscience, Inc.: Magellan Diagnostics, Inc. Expands Voluntary Recall Of LeadCare Test Kits Benzinga

Aug 9, 2021

06:34AM EDT HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Lowers Price Target to $27 Benzinga

Aug 6, 2021

08:27AM EDT Meridian Bioscience: Q3 Earnings Insights Benzinga

08:07AM EDT Meridian Bioscience Reaffirms FY21 Sales Guidance $308M-$314M vs $326M Estimate, Adj. EPS $1.61-$1.67 vs $1.72 Est. Benzinga

08:06AM EDT Meridian Bioscience Q3 Adj. EPS $0.22 Misses $0.31 Estimate, Sales $63.51M Miss $77.22M Estimate Benzinga

08:00AM EDT Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2021. GlobeNewswire Inc

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

04:22AM EDT Earnings Scheduled For August 6, 2021 Benzinga

Aug 2, 2021

09:00AM EDT Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the previously announced acquisition of the North American BreathTek business from Otsuka America Pharmaceutical, Inc. effective July 31, 2021. GlobeNewswire Inc

Jul 29, 2021

07:01PM EDT Intec Pharma, GreenTree & MedMen Among Top Cannabis Stock Movers On July 29, 2021 Benzinga

Jul 27, 2021

05:48PM EDT AusCann, Meridian Bioscience & General Cannabis Among Top Cannabis Stock Movers On July 27, 2021 Benzinga

Jul 23, 2021

10:39AM EDT Meridian To Buy Urea Breath Test For H. Pylori From Otsuka America Pharmaceutical For $20M Benzinga

09:20AM EDT Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek business from Otsuka America Pharmaceutical, Inc. for $20 million in cash. The transaction is expected to close in Meridians fiscal fourth quarter. GlobeNewswire Inc

Jul 22, 2021

05:48PM EDT Rhinomed, Alcanna & MariMed Among Top Cannabis Stock Movers On July 22, 2021 Benzinga

Jul 19, 2021

05:05PM EDT Bearish Sentiment Toward Market: Cannabis Movers For July 19, 2021 Benzinga

Jul 17, 2021

11:19AM EDT C21 Investments, 1933 Industries And Urban-Gro Among Top Cannabis Stock Movers On June 16, 2021 Benzinga

Jul 15, 2021

07:52AM EDT Bearish Sentiment On The Marijuana Market: Cannabis Movers For July 14, 2021 Benzinga

Jul 14, 2021

09:02AM EDT Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter fiscal 2021 financial results Friday, August 6, 2021. GlobeNewswire Inc

07:14AM EDT General Cannabis, MariMed & Urban-Gro Among Top Cannabis Stock Movers On July 13, 2021 Benzinga

Jul 13, 2021

02:38PM EDT Mid-Afternoon Market Update: Dow Falls 75 Points; Red Cat Holdings Shares Spike Higher Benzinga

12:05PM EDT Mid-Day Market Update: Howard Bancorp Jumps Following Merger News; Gatos Silver Shares Slide Benzinga

10:21AM EDT Shares of Meridian Bioscience, Inc. (VIVO) are falling more than 14% Tuesday morning after the diagnostic testing solutions provider announced preliminary third-quarter revenue, that fell short of the Street view. RTTNews

09:05AM EDT Meridian Bioscience Sees Prelim. Q3 Revenue $63.5M vs $77.22M Est. Benzinga

09:01AM EDT Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided preliminary revenue results for its third quarter of fiscal 2021. GlobeNewswire Inc

Jun 28, 2021

09:26AM EDT Meridian Bioscience Says Resubmits Application To FDA For Emergency Use Authorization For Revogene SARS-CoV-2 Molecular Assay Benzinga

09:25AM EDT Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has re-submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the companys SARS-CoV-2 molecular diagnostic test on the Revogene platform. GlobeNewswire Inc

Jun 16, 2021

09:00AM EDT Meridians New Master Mix for LAMP Assays Offers GlobeNewswire Inc

Jun 7, 2021

04:54PM EDT Cannabis Stock Gainers And Losers From June 7, 2021 Benzinga

09:42AM EDT Overview Of Value Stocks In The Healthcare Sector Benzinga

Jun 2, 2021

05:03PM EDT Cannabis Stock Gainers And Losers From June 2, 2021 Benzinga

May 27, 2021

10:00AM EDT Meridian Bioscience to Participate in the 41st Annual William GlobeNewswire Inc

May 26, 2021

05:28PM EDT Cannabis Stock Gainers And Losers From May 26, 2021 Benzinga

May 17, 2021

11:01AM EDT Meridian Bioscience Highlights Air-Dryable qPCR Mix For Crude Plant Samples Benzinga

10:00AM EDT Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable Direct DNA qPCR Plant Mix. This unique Mix is specifically designed to develop and manufacture multiplexed highly sensitive and economical molecular field-tests in agriculture biotechnology (AgBio). GlobeNewswire Inc

09:45AM EDT A Look Into Healthcare Sector Value Stocks Benzinga

May 13, 2021

05:00PM EDT Cannabis Stock Gainers And Losers From May 13, 2021 Benzinga

May 10, 2021

10:07AM EDT Meridian Bioscience shares were trading higher after HC Wainwright & Co. maintained its Buy rating on the stock. Benzinga

07:16AM EDT HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Lowers Price Target to $30 Benzinga

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

07:39AM EDT Meridian Bioscience Sees FY21 Adj. EPS $1.60-$1.80 vs $1.66 Est., Sales $305M-$355M vs $324.35M Est. Benzinga

07:38AM EDT Meridian Bioscience Q2 Adj. EPS $0.56 Beats $0.48 Estimate, Sales $85.30M Beat $84.48M Estimate Benzinga

07:30AM EDT Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021. GlobeNewswire Inc

04:12AM EDT Earnings Scheduled For May 7, 2021 Benzinga

Apr 28, 2021

02:00PM EDT Meridian Simplifies Workflows for POC Molecular Tests with a New GlobeNewswire Inc

Apr 27, 2021

05:01PM EDT Cannabis Stock Gainers And Losers From April 27, 2021 Benzinga

Apr 21, 2021

03:34PM EDT Cannabis Stock Gainers And Losers From February 23, 2021 Benzinga

Apr 19, 2021

02:00PM EDT Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter fiscal 2021 financial results Friday, May 7, 2021. GlobeNewswire Inc

Apr 1, 2021

09:37AM EDT Meridian Bioscience Makes 510(k) Submission To FDA For New Curian Campy Assay RTTNews

09:37AM EDT Meridian Bioscience Announces FDA Submission for New GlobeNewswire Inc

09:37AM EDT Meridian Bioscience Announces FDA Submission For New Curian Campy Assay Benzinga

Mar 8, 2021

10:00AM EST Meridian Bioscience Says Launches Its new Air-Dryable Mix For Crude Blood Samples Benzinga

10:00AM EST Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable Direct DNA qPCR Blood Mix, which is specifically designed for the manufacturing of room-temperature stable molecular diagnostic assays direct from whole blood, serum or plasma. GlobeNewswire Inc

Mar 4, 2021

09:00AM EST Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H.C. Wainwright Global Life Sciences 2021 Virtual Conference. Jack Kenny, Chief Executive Officer, will pre-record a presentation that will be available on March 9, 2021. GlobeNewswire Inc

Feb 26, 2021

10:31AM EST IIROC Trade Resumption - VIVO.WT PR Newswire

08:20AM EST IIROC Trading Halt - VIVO.WT PR Newswire

Feb 24, 2021

06:34AM EST HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Lowers Price Target to $32 Benzinga

Feb 23, 2021

05:44PM EST Cannabis Stock Gainers And Losers From February 23, 2021 Benzinga

01:19PM EST Meridian Bioscience Says FDA, In Communication From Tuesday, Clarified 'Meridian will not be able to distribute its SARS-CoV-2 molecular diagnostic test on its Revogene platform until the test receives EUA approval from the FDA' Benzinga

01:17PM EST Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the withdrawal of its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene platform. GlobeNewswire Inc

09:33AM EST Meridian Bioscience Pulls Out Revogene COVID-19 Test EUA Application Benzinga

08:06AM EST Meridian Biosciences Says On Feb. 22 Co Elected To Withdraw Emergency Use Authorization For SARS-CoV-2 Molecular Diagnostic Test On Revogene Platform Benzinga

08:00AM EST Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided a further update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene platform. GlobeNewswire Inc

Feb 17, 2021

06:32PM EST Cannabis Stock Gainers And Losers From February 17, 2021 Benzinga

Feb 16, 2021

08:44AM EST Meridian Biosciences Says Placing Shipments Of SARS-CoV-2 Testing Kits On Hold; Says On Feb. 12 FDA Requested Additional Info On COVID-19 Molecular Diagnostic Test On Revogene Platform Emergency Use Application; Says Plans To Submit Response To FDA Today Benzinga

08:00AM EST Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided an update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene platform. GlobeNewswire Inc

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 8, 2021

06:49AM EST HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $34 Benzinga

Feb 5, 2021

07:47AM EST Meridian Bioscience: Q1 Earnings Insights Benzinga

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

07:36AM EST Meridian Bioscience Sees FY21 Adj. EPS $1.70-$1.90 vs $1.22 Est., Sales $320M-$350M vs $307.42M Est. Benzinga

07:34AM EST Meridian Bioscience Q1 EPS $0.65 Beats $0.42 Estimate, Sales $92.90M Beat $83.89M Estimate Benzinga

07:30AM EST Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2020. GlobeNewswire Inc

03:36AM EST Earnings Scheduled For February 5, 2021 Benzinga

Feb 3, 2021

10:32AM EST Meridian Bioscience Reports Will Increase Production Capacity Of Co.'s SARS-CoV-2 Molecular Diagnostic Test On Its Revogene Platform Benzinga

10:30AM EST Meridian Bioscience Expands Production Capacity with Support from GlobeNewswire Inc

Feb 2, 2021

08:01AM EST Meridians Air-Dryable Master Mixes Replace GlobeNewswire Inc

Jan 30, 2021

01:19PM EST The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More Benzinga

Jan 13, 2021

04:30PM EST Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter fiscal 2021 financial results Friday, February 5, 2021. GlobeNewswire Inc

Jan 7, 2021

08:16AM EST Meridian Bioscience Expects Q1 Revenue To Be $92 Mln RTTNews

08:03AM EST Meridian Bioscience Sees Q1 Sales ~$92M Vs. $78.71M Est. Benzinga

08:00AM EST Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced preliminary financial results for the first quarter of fiscal 2021. GlobeNewswire Inc

Jan 6, 2021

09:30AM EST Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H. C. Wainright Bioconnect 2021 Virtual Conference. Jack Kenny, Chief Executive Officer, will pre-record a fireside chat that will be available on January 11, 2021. GlobeNewswire Inc

Dec 17, 2020

11:20AM EST Bioscience, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire

Dec 16, 2020

03:01PM EST Meridian Bioscience Wins $1M In Funding By National Institute Of Health Rapid Acceleration Of Diagnostics Initiative Benzinga

03:00PM EST Meridian Bioscience receives NIH Award for supporting rapid GlobeNewswire Inc

Dec 8, 2020

10:18AM EST Meridian Bioscience Reports Submission Of FDA Application For Emergency Use Authorization Of Its SARS-CoV-2 Molecular Assay Benzinga

10:17AM EST Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the companys SARS-CoV-2 molecular diagnostic test on the Revogene platform. GlobeNewswire Inc

Dec 3, 2020

10:01AM EST Meridian Launches its Novel Air-Dryable RT-qPCR Mix Benzinga

10:00AM EST Meridian Launches its Novel Air-Dryable RT-qPCR Mix, Further GlobeNewswire Inc

Nov 23, 2020

10:00AM EST Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer pre-recorded a fireside chat on Tuesday, November 17, 2020. GlobeNewswire Inc

Nov 16, 2020

12:00PM EST Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a live stream fireside chat at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 at 12:30pm ET. GlobeNewswire Inc

08:12AM EST 10 Biggest Price Target Changes For Monday Benzinga

06:29AM EST HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Lowers Price Target to $30 Benzinga

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

07:35AM EST Meridian Bioscience Sees FY21 Adj. EPS $1.14-$1.28 vs $0.95 Est., Sales $290M-$310M vs $262.41M Est. Benzinga

07:33AM EST Meridian Bioscience Q4 Adj. EPS $0.19 Beats $0.14 Estimate, Sales $64.20M Beat $59.64M Estimate Benzinga

07:30AM EST Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2020. GlobeNewswire Inc

04:18AM EST Earnings Scheduled For November 13, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Oct 20, 2020

11:00AM EDT Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report fourth quarter and full year 2020 financial results Friday, November 13, 2020. GlobeNewswire Inc

Oct 7, 2020

09:08AM EDT Meridian Biosciences Launches Complete Solution To Support Liquid Biopsy Cancer Diagnostics Benzinga

09:00AM EDT Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a complete solution improving the development of cancer diagnostic tests, allowing direct RNA and DNA detection from liquid biopsy samples such as whole blood. GlobeNewswire Inc

08:07AM EDT IIROC Trade Resumption - VIVO PR Newswire

Oct 6, 2020

03:31PM EDT IIROC Trading Halt - VIVO PR Newswire

Sep 14, 2020

10:08AM EDT Meridian Launches SARS-CoV-2 Antibody Pair Designed For Developing Sensitive Rapid Antigen Tests From Saliva Samples RTTNews

10:03AM EDT Meridian Biosciences Launches Novel SARS-CoV-2 Antibody Pair Designed For Developing Highly Sensitive Rapid Antigen Tests From Saliva Samples Benzinga

10:00AM EDT Meridian launches a novel SARS-CoV-2 antibody pair designed for GlobeNewswire Inc

Aug 31, 2020

08:00AM EDT Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will present at the H. C. Wainright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 12:30pm ET. GlobeNewswire Inc

Aug 7, 2020

11:00AM EDT Meridian Bioscience shares are trading higher after the company reported Q3 EPS results up from last year and better-than-expected sales results. The company also raised its FY20 EPS and sales guidance above analyst estimates. UPDATE: Shares have since reversed, now lower. Benzinga

07:34AM EDT Meridian Biosciences Raises FY20 Guidance: Sales From $230M-$236M To $245M-$250M vs $235.6M Estimate, Adj. EPS From $0.70-$0.75 To $1.01-$1.05 vs $0.75 Est. Benzinga

07:33AM EDT Meridian Bioscience Q3 Adj. EPS $0.55 Up From $0.16 YoY, Sales $84.80M Beat $66.04M Estimate Benzinga

07:30AM EDT Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fiscal third quarter ended June 30, 2020. GlobeNewswire Inc

04:02AM EDT Earnings Scheduled For August 7, 2020 Benzinga

Aug 6, 2020

04:00PM EDT Earnings Outlook for Meridian Bioscience Benzinga

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

Jul 28, 2020

09:11AM EDT Meridian Bioscience Appoints Anthony Bihl To Its Board RTTNews

09:00AM EDT Meridian Bioscience, Inc. (NASDAQ: VIVO) announces the appointment of Anthony Bihl III to its Board of Directors, effective immediately. GlobeNewswire Inc

Jul 27, 2020

09:33AM EDT Benzinga's Top Upgrades, Downgrades For July 27, 2020 Benzinga

06:42AM EDT HC Wainwright & Co. Initiates Coverage On Meridian Bioscience with Buy Rating, Announces Price Target of $34 Benzinga

Jul 16, 2020

09:00AM EDT Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter 2020 financial results Friday, August 7, 2020. GlobeNewswire Inc

Jul 13, 2020

01:02PM EDT Meridian Biosciences Announces Launch Of High-Sensitivity Coronavirus Nucleocapsid Antibody Pair For The Development Of Rapid Coronavirus Antigen Assays Benzinga

01:00PM EDT Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a high-sensitivity SARS-CoV-2 nucleocapsid antibody pair for the development of rapid COVID-19 antigen assays. GlobeNewswire Inc